These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 31668671)

  • 1. Corrigendum to "Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis" [J Hepatol 71 (2019) 543-552].
    Yau T; Hsu C; Kim TY; Choo SP; Kang YK; Hou MM; Numata K; Yeo W; Chopra A; Ikeda M; Kuromatsu R; Moriguchi M; Chao Y; Zhao H; Anderson J; Dela Cruz C; Kudo M
    J Hepatol; 2019 Dec; 71(6):1278. PubMed ID: 31668671
    [No Abstract]   [Full Text] [Related]  

  • 2. Corrigendum to "Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies" [J hepatol 67 (2017) 999-1008].
    Bruix J; Cheng AL; Meinhardt G; Nakajima K; De Sanctis Y; Llovet J
    J Hepatol; 2018 Oct; 69(4):990-991. PubMed ID: 30104026
    [No Abstract]   [Full Text] [Related]  

  • 3. Corrigendum to: "Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma" [J Hepatol (2020) 121-129].
    Kim N; Cheng J; Jung I; Liang J; Shih YL; Huang WY; Kimura T; Lee VHF; Zeng ZC; Zhenggan R; Kay CS; Heo SJ; Won JY; Seong J
    J Hepatol; 2020 Nov; 73(5):1295-1296. PubMed ID: 32921509
    [No Abstract]   [Full Text] [Related]  

  • 4. Corrigendum to "EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma" [J Hepatol 69 (2018) 182-236].
    European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu
    J Hepatol; 2019 Apr; 70(4):817. PubMed ID: 30739718
    [No Abstract]   [Full Text] [Related]  

  • 5. Corrigendum to "Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma" [J Hepatol 67 (2017) 293-301].
    Huang A; Zhao X; Yang XR; Li FQ; Zhou XL; Wu K; Zhang X; Sun QM; Cao Y; Zhu HM; Wang XD; Yang HM; Wang J; Tang ZY; Hou Y; Fan J; Zhou J
    J Hepatol; 2017 Nov; 67(5):1123. PubMed ID: 28916407
    [No Abstract]   [Full Text] [Related]  

  • 6. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.
    Liu Z; Lin Y; Zhang J; Zhang Y; Li Y; Liu Z; Li Q; Luo M; Liang R; Ye J
    J Exp Clin Cancer Res; 2019 Nov; 38(1):447. PubMed ID: 31684985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corrigendum to "Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B" [J Hepatol 69 (2018) 278-285].
    Hsu YC; Yip TC; Ho HJ; Wong VW; Huang YT; El-Serag HB; Lee TY; Wu MS; Lin JT; Wong GL; Wu CY
    J Hepatol; 2019 Mar; 70(3):581. PubMed ID: 30635242
    [No Abstract]   [Full Text] [Related]  

  • 8. Nivolumab for the treatment of hepatocellular carcinoma.
    Finkelmeier F; Waidmann O; Trojan J
    Expert Rev Anticancer Ther; 2018 Dec; 18(12):1169-1175. PubMed ID: 30304963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Corrigendum to: "BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA" [J Hepatol (2020) 1-13].
    Hirsch TZ; Negulescu A; Gupta B; Caruso S; Noblet B; Couchy G; Bayard Q; Meunier L; Morcrette G; Scoazec JY; Blanc JF; Amaddeo G; Nault JC; Bioulac-Sage P; Ziol M; Beaufrère A; Paradis V; Calderaro J; Imbeaud S; Zucman-Rossi J
    J Hepatol; 2020 Jul; 73(1):225-226. PubMed ID: 32360197
    [No Abstract]   [Full Text] [Related]  

  • 10. Corrigendum to "Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules" [J Hepatol (2019) 874-884].
    Mariño Z; Darnell A; Lens S; Sapena V; Díaz A; Belmonte E; Perelló C; Calleja JL; Varela M; Rodriguez M; Rodriguez de Lope C; Llerena S; Torras X; Gallego A; Sala M; Morillas RM; Minguez B; Llaneras J; Coll S; Carrion JA; Iñarrairaegui M; Sangro B; Vilana R; Sole M; Ayuso C; Ríos J; Forns X; Bruix J; Reig M
    J Hepatol; 2021 Feb; 74(2):491. PubMed ID: 33317846
    [No Abstract]   [Full Text] [Related]  

  • 11. Corrigendum to 'Genomic sequencing identifies WNK2 as a driver in hepatocellular carcinoma and a risk factor for early recurrence' [J Hepatol 71 (2019) 1152-63].
    Zhou SL; Zhou ZJ; Hu ZQ; Song CL; Luo YJ; Luo CB; Xin HY; Yang XR; Shi YH; Wang Z; Huang XW; Cao Y; Fan J; Zhou J
    J Hepatol; 2022 Apr; 76(4):990. PubMed ID: 35151501
    [No Abstract]   [Full Text] [Related]  

  • 12. Corrigendum to "Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma" [J Hepatol 2015;62:607-616].
    Yeung OW; Lo CM; Ling CC; Qi X; Geng W; Li CX; Ng KT; Forbes SJ; Guan XY; Poon RT; Fan ST; Man K
    J Hepatol; 2016 Jun; 64(6):1461. PubMed ID: 27198050
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinical research progression of molecular-targeted drugs and PD-1 inhibitors for advanced hepatocellular carcinoma].
    Lai JM; Hu S; Lin H; Luo H; Luo YB
    Zhonghua Zhong Liu Za Zhi; 2019 Jun; 41(6):406-409. PubMed ID: 31216824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Corrigendum to 'Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis' [J Hepatol 75 (2021) 865-878].
    Pinyol R; Torrecilla S; Wang H; Montironi C; Piqué-Gili M; Torres-Martin M; Wei-Qiang L; Willoughby CE; Ramadori P; Andreu-Oller C; Taik P; Lee YA; Moeini A; Peix J; Faure-Dupuy S; Riedl T; Schuehle S; Oliveira CP; Alves VA; Boffetta P; Lachenmayer A; Roessler S; Minguez B; Schirmacher P; Dufour JF; Thung SN; Reeves HL; Carrilho FJ; Chang C; Uzilov AV; Heikenwalder M; Sanyal A; Friedman SL; Sia D; Llovet JM
    J Hepatol; 2021 Dec; 75(6):1515. PubMed ID: 34627652
    [No Abstract]   [Full Text] [Related]  

  • 15. Corrigendum to: 'Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target' [J Hepatol 2021 (74) 1155-1166].
    Ningarhari M; Caruso S; Hirsch TZ; Bayard Q; Franconi A; Védie AL; Noblet B; Blanc JF; Amaddeo G; Ganne N; Ziol M; Paradis V; Guettier C; Calderaro J; Morcrette G; Kim Y; MacLeod AR; Nault JC; Rebouissou S; Zucman-Rossi J
    J Hepatol; 2022 May; 76(5):1242-1243. PubMed ID: 35221117
    [No Abstract]   [Full Text] [Related]  

  • 16. Corrigendum to "Joint Consensus Statement of the Indian National Association for Study of the Liver and Indian Radiological and Imaging Association for the Diagnosis and Imaging of Hepatocellular Carcinoma Incorporating Liver Imaging Reporting and Data System" [J Clin Expt Hepatol 9 (2019) 625-651].
    Krishan S; Dhiman RK; Kalra N; Sharma R; Baijal SS; Arora A; Gulati A; Eapan A; Verma A; Keshava S; Mukund A; Deva S; Chaudhary R; Ganesan K; Taneja S; Gorsi U; Gamanagatti S; Madhusudan KS; Puri P; Shalimar ; Govil S; Wadhavan M; Saigal S; Kumar A; Thapar S; Duseja A; Saraf N; Khandelwal A; Mukhopadyay S; Gulati A; Shetty N; Verma N
    J Clin Exp Hepatol; 2020; 10(2):188. PubMed ID: 32189936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic Treatment of Patients with Advanced, Unresectable Hepatocellular Carcinoma: Emergence of Therapies.
    Sun W; Cabrera R
    J Gastrointest Cancer; 2018 Jun; 49(2):107-115. PubMed ID: 29453759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Corrigendum to: "PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma" [J Hepatol 77 (2022) 163-176].
    Wei CY; Zhu MX; Zhang PF; Huang XY; Wan JK; Yao XZ; Hu ZT; Chai XQ; Peng R; Yang X; Gao C; Gao J; Wang SW; Zheng YM; Tang Z; Gao Q; Zhou J; Cai JB; Ke AW; Fan J
    J Hepatol; 2023 Apr; 78(4):881-882. PubMed ID: 36564318
    [No Abstract]   [Full Text] [Related]  

  • 19. Feasibility and safety of nivolumab in advanced hepatocellular carcinoma: real-life experience from three German centers.
    Finkelmeier F; Czauderna C; Perkhofer L; Ettrich TJ; Trojan J; Weinmann A; Marquardt JU; Vermehren J; Waidmann O
    J Cancer Res Clin Oncol; 2019 Jan; 145(1):253-259. PubMed ID: 30374657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Corrigendum to "Correlation of Clinicopathological Profile, Prognostic Factors, and Survival Outcomes with Baseline Alfa-Fetoprotein Levels in Patients with Hepatocellular Carcinoma: A Biomarker that is Bruised but Not Broken" [J Clin Exp Hepatol 12 (2022) 841-852].
    Jearth V; Patil PS; Mehta S; Sundaram S; Seth V; Goel M; Patkar S; Bal M; Rao V
    J Clin Exp Hepatol; 2022; 12(6):1597. PubMed ID: 36340311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.